12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Cimzia certolizumab pegol: Postmarketing study started

UCB began the single-blind, international postmarketing EXXELERATE trial comparing Cimzia plus methotrexate vs. Humira plus methotrexate for 104 weeks in about 900 patients who have responded inadequately to methotrexate and who have not previously received anti-TNF treatment. After 12 weeks, non-responders will...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >